Key result
The bradykinin B2 receptor antagonist HOE-140 did not prevent the attenuation of vasodilatation by ischaemia-reperfusion injury.
Why the study?
Does intravenous HOE-140 (bradykinin B2 receptor antagonist) alter endothelium-dependent vasomotor dysfunction induced by ischaemia-reperfusion injury or the protection afforded by remote ischaemic preconditioning in healthy male volunteers?
RCT (n=20)
Double-blind
cross-over
No
Does intravenous HOE-140 (bradykinin B2 receptor antagonist) alter endothelium-dependent vasomotor dysfunction induced by ischaemia-reperfusion injury or the protection afforded by remote ischaemic preconditioning in healthy male volunteers?
Endogenous bradykinin acting via the B2 receptor does not appear to mediate ischaemia-reperfusion injury or the protective effects of remote ischaemic preconditioning in humans.
Answers are grounded in this paper and cite their sources.
B2 blockade confers no endothelial protection in IR injury; confirms bradykinin does not mediate this or RIPC effects in humans.
OBJECTIVE: To examine whether endogenous bradykinin mediates the endothelium-dependent vasomotor dysfunction induced by ischaemia-reperfusion injury, or the protection afforded by remote ischaemic preconditioning in vivo in man. DESIGN: Randomised double-blind, cross-over study. SETTINGS: Royal Infirmary of Edinburgh, Wellcome Trust Clinical Research Facility. PATIENTS: Twenty healthy male volunteers. INTERVENTIONS: Subjects were randomised to intravenous infusion of the bradykinin B(2) receptor antagonist, HOE-140 (100 μg/kg), or saline placebo in a double-blind, crossover trial. Ischaemia-reperfusion injury was induced in the non-dominant arm by inflating a cuff to 200 mm Hg for 20 min in all subjects. Ischaemia-reperfusion injury was preceded by three cycles of remote ischaemic preconditioning in the dominant arm in 10 subjects. MAIN OUTCOME MEASURES: Bilateral forearm blood flow was assessed using venous occlusion plethysmography during intra-arterial infusion of acetylcholine (5-20 μg/min). RESULTS: Acetylcholine caused vasodilatation in all studies (p<0.05) that was attenuated by ischaemia-reperfusion injury, both in the presence (p=0.0002) and absence (p=0.04) of HOE-140. Remote ischaemic preconditioning abolished the impairment of endothelium-dependent vasomotor function induced by ischaemia-reperfusion injury. HOE-140 had no effect on the protection afforded by remote ischaemic preconditioning. CONCLUSIONS: These findings do not support a major role for endogenous bradykinin, acting via the B(2) kinin receptor, in the mechanism of ischaemia-reperfusion injury or the protective effects of remote ischaemic preconditioning in man. CLINICAL TRIAL REGISTRATION INFORMATION: NCT00965120 and NCT00965393.
No takes yet. Share an insight, caveat, or question.
Pedersen et al. (2011) conducted an RCT in Ischaemia-reperfusion injury (n=20). HOE-140 vs. saline placebo was evaluated on Bilateral forearm blood flow assessed using venous occlusion plethysmography during intra-arterial infusion of acetylcholine. The bradykinin B2 receptor antagonist HOE-140 did not prevent the attenuation of vasodilatation by ischaemia-reperfusion injury.
Synapse has enriched 10 related papers. Consider them for comparative context: